As a leading National Cancer Institute comprehensive cancer center, City of Hope® Duarte is recognized for its excellence in advancing treatment and research protocols. City of Hope is also ranked among the top five hospitals for cancer in the nation by U.S. News & World Report — the highest such ranking in California.

Our blood cancer experts in the Los Angeles and Southern California region offer high-quality care and treatments for myeloma. City of Hope is among a dozen national centers treating myeloma with a coordinated, multidisciplinary team solely focused on this type of cancer. Our myeloma specialists aim to control the disease so that our patients can live longer and maintain an active life.

Treatment for myeloma and multiple myeloma is rapidly advancing, and with the approval of new agents, survival rates for myeloma patients are on the rise. City of Hope is at the forefront of that progress as a comprehensive cancer center. We were involved in pivotal early trials of two drugs — daratumumab and ixazomib — that are now part of myeloma therapy worldwide.

Myeloma Care in Los Angeles

City of Hope's Los Angeles-area myeloma experts provide leading-edge care and perform innovative research to understand the disease better and tailor treatment to each patient's goals and myeloma type. Our team combines deep experience and diverse perspectives to arrive at the ideal treatment for you. Your care includes regular interaction and input from hematologists, oncologists, radiologists, pathologists, nurses, social workers and specially trained support staff. Our survivorship clinics support and monitor you throughout and after treatment.

With an additional 30 clinical network locations throughout the Los Angeles area, we are committed to offering continuity of care that supports you at every stage of the diagnosis, treatment and recovery process.

What Sets Our Los Angeles-Area Myeloma Program Apart?

At City of Hope, we are committed to making a difference in the lives of our patients by developing curative therapies that may play a role in treatment. Our goal is to slow down the disease progression, extend remission time and reduce symptoms. We offer access to dozens of clinical trials and new therapies not always available elsewhere.

  • Our experienced doctors specialize in treating high-risk or relapsed myeloma and those who have undergone failed therapies.
  • We prioritize quality of life by minimizing drug toxicity and tailoring therapy to include medications that deal with common disease-related bone problems.
  • Our Judy and Bernard Briskin Center for Multiple Myeloma Research is among the largest programs of its kind in California. We lead the development of over 15 active clinical trials for all multiple myeloma stages and aim to make multiple myeloma and related light-chain amyloidosis manageable and nonlethal through immunotherapy and rational combinatorial therapies.
  • Our Kenneth Goldman and Briskin Family Clinical Trials Program offers promising therapies — gene, CAR T cell, and antibody — as part of our ongoing clinical trials aimed at identifying even more effective immunotherapy treatments. These include exciting advances in CAR T cell therapy, checkpoint inhibitors, bispecific antibodies, and novel antibody-drug conjugates.
  • We are home to one of the most prominent U.S. blood stem cell and bone marrow transplant centers, and our innovative approaches include combining transplantation with new therapies. Our highly trained nurses offer outpatient support for bone marrow transplant patients.
  • Our research focuses on new drugs and drug combinations that target and attack relapsed myeloma that has become resistant to first-line treatment.
  • We collaborate with the Multiple Myeloma Research Consortium.
  • We customize genetic testing and drug therapy to the molecular profile of specific myeloma types, using computer models to predict toxicity and tailor treatments for efficacy and fewer side effects.
  • Our collaborative approach, combined with our dedication to advancing cancer care, results in superior myeloma cancer survival outcomes compared to Los Angeles SEER registry data.

Our Los Angeles-Area Myeloma Program Recognitions

City of Hope is ranked among the Highest Performing Hospitals for Leukemia, Lymphoma & Myeloma by U.S. News & World Report 2024-25


City of Hope consistently ranks among U.S. News and World Report’s list of best hospitals for cancer in the United States, with consecutive rankings for nearly two decades.

In addition, U.S. News rated City of Hope Duarte as “high performing” for myeloma treatment.
 

Our Los Angeles-Area Myeloma Experts

Myeloma Leadership

Make an Appointment with Our Los Angeles-Area Myeloma Team

Myeloma Expertise Matters

The world-renowned team at City of Hope offers a deep understanding of the latest myeloma treatments. Our expertise comes from treating cancer, including rare and complex cases, daily.

Call to become a patient, get a second opinion, or make a referral.

Aerial of Duarte Campus

Blood Cancer News